MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by
MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by Boston Scientific, codevelopment responsibilities for integrating Boston Scientific's device platforms with MediGuide's proprietary guidance system, exclusive global distribution, and an option for Boston Scientific to acquire MediGuide at a future time.
The cornerstone of the alliance is an advanced navigation system developed by the Arlington, VA, company. The Medical Positioning System (MPS) enables real-time tracking of miniature sensors integrated into therapeutic and diagnostic medical devices. These devices register their exact location and orientation utilizing advanced diagnostic systems such as Boston Scientific's intravascular ultrasound system, as well as other diagnostic systems including x-ray angiography, MR, and CT. Boston Scientific and MediGuide plan to integrate the MPS with Boston Scientific's IVUS.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.